IL1RL1 and COVID-19: Collectively, the IL-33/ST2 axis remarkably reduces pDCs-dependent IFN-I production by inhibiting the biological activity of the IRAK1/TRL7 pathway, thereby increasing the susceptibility of COVID-19 patients to the virus in the early to middle stage, especially for patients with insufficient circulating IFN levels.